Re-Check
Randomized phase II, open-label efficacy and safety study of second-line durvalumab plus tremelimumab versus platinum-based chemotherapy alone in patients with NSCLC and first-line checkpoint-inhibitor therapy followed by 2 cycles of platinum-based chemotherapy
II
interventionell
National
Durvalumab, Tremelimumab
Status: Studie beendet
Zeitraum
2022
2022
Zentren
Keine Zentren gesucht
27.10.2022
Klinische Settings
IV
2nd line
palliativ
Identifier
AIO-TRK-0221
AIO-TRK-0221
2017-003780-35
Kontakt
Leitung
Prof. Dr. med. Niels Reinmuth
Ansprechpartner*in
Sophie Worthmann
Telefon +49 30 814534461
E-Mail ReCheck@aio-studien-ggmbh.de